Stella Pharma: Announcements of individual stocks regarding the implementation of transportation validation for our commercial export for the People's Republic of China Hainan Island business.
Stella Pharma: Announcements of individual stocks regarding the monthly exercise status of the 4th subscription rights (with exercise price adjustment clause).
Stella Pharma: Announcements of subscription rights for the 4th time (with exercising price revision clause) regarding the mass exercise.
Stella Pharma: Bylaws 25th June 2024
Stella Pharma: Regarding matters related to dominant shareholders.
Stella Pharma: Matters related to business plans and growth potential.
Stella Pharma: Announcements of individual stocks: Notification of submission of a clinical trial plan for domestic Phase I/II clinical trial of BNCT targeting malignant tumors of the chest.
Stella Pharma: Announcements of subscription rights for the 4th time (with exercising price revision clause) regarding the mass exercise.
Stella Pharma: Announcements of individual stocks regarding the receipt of collateral in the People's Republic of China, Hainan Island operation.
Stella Pharma: Notice regarding the monthly exercise status of the 4th Stock Acquisition Rights (with exercise price amendment clause)
Stella Pharma: Notice regarding the formulation of the Mid-Term Management Plan 2027
Stella Pharma: Independent Officer Notification Form
Stella Pharma: Notice regarding partial changes to the Articles of Incorporation
Stella Pharma: Notice regarding the introduction of a performance-linked share system with transfer restrictions for our employees
Stella Pharma: Notice regarding the introduction of an ex post grant type performance-linked share reward system with transfer restrictions
Stella Pharma: Notice regarding a decrease in the amount of capital and capital reserves and disposal of other capital surpluses (compensation for losses in carryforward retained earnings)
Stella Pharma: 2024 financial results overview
Stella Pharma: Notice regarding the conclusion of a letter of intent (MOU) with the Hong Kong-Shenzhen Innovation and Technology Park Management and Operation Company
Stella Pharma: Notice of publication of a paper on clinical research on boron neutron capture therapy for recurrent breast cancer
Stella Pharma: Notice of posting advertisements for our articles in Nature
No Data